Grants for Nonprofits - Federal

The U.S. Embassy Kigali Public Diplomacy Section (PD) of the U.S. Department of State is pleased to announce that funding is available through its Public Diplomacy Small Grants Program. This is an Annual Program Statement, outlining our funding priorities, the strategic themes we focus on, and the procedures for submitting requests for funding. Please carefully follow all instructions below.Purpose of Small Grants: We invite proposals for programs that strengthen cultural ties between the U.S. and Rwanda through cultural and exchange programming that highlights shared values and promotes bilateral cooperation. All programs must include an American cultural element, or connection with American expert/s, organization/s, or institution/s in a specific field that will promote increased understanding of U.S. policy and perspectives.Examples of PD Small Grants Program programs include, but are not limited to: Academic and professional lectures, seminars and speaker programs; Artistic and cultural workshops, joint performances and exhibitions; Cultural heritage conservation and preservation programs; Professional and academic exchanges and programs;

The NICHD Small Research Grant Program (R03 Clinical Trial Required) supports clinical trials that fall within the NICHD mission. The R03 activity code supports small research projects that can be carried out in a short period of time with limited resources. The R03 program may be used for different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

This funding opportunity supports research projects aimed at improving cancer care and outcomes for sexual and gender minority survivors by addressing healthcare disparities and enhancing access to quality treatment.

This funding opportunity provides financial support for organizations to evaluate and implement overdose prevention strategies targeting communities disproportionately affected by substance use disorders and overdose deaths.

Orthopaedic injuries have a profound impact on military readiness and return to work/activity/duty. In the military, extremity battle wounds comprise approximately 50% of injuries reported in the Department of Defense Trauma Registry. Additionally, orthopaedic injuries and conditions that occur outside of combat (e.g., during training, leisure activities, resultant from old injuries) present one of the greatest threats to the readiness of our Service Members and military. Early stabilization, treatment, and rehabilitation of orthopaedic injuries in both civilian and military populations have led to better outcomes, particularly in the prevention of secondary complications and in minimizing morbidity. Availability of orthopaedic care and treatment as early as possible, or as close to the point of injury as possible, also minimizes limb loss and affects military readiness.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the selected Focus Area.The PRORP CTA supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of military combat or service-related orthopaedic injuries that significantly impact unit readiness and return-to-duty/work rates. Applicants are encouraged to address how the proposed research will support patient care closer to the point of injury and/or allow patients to more quickly return to duty/work. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.The FY24 PRORP CTA differs from the FY24 PRORP Clinical Translational Research Award (CTRA) in that the CTRA allows for clinical research projects that may or may not include a clinical trial, whereas the CTA is restricted to clinical trials only.Funding from this award mechanism must support a clinical trial and may not be used for animal or preclinical studies. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.All applications submitted to this program announcement, regardless of the selected Focus Area, are eligible for Research Level 1.Collaborative Care Option (Research Level 2): Applications submitted to the FY24 PRORP CTA, with Focus Area Translation of Early Findings Soft Tissue Trauma, are eligible for a Collaborative Care Option (Research Level 2); refer to Section II.D.5, Funding Restrictions. The Collaborative Care Option provides additional support to encourage collaborative interdisciplinary research among physical therapists, occupational therapists, prosthetists, surgeons, and other orthopaedic care providers. The proposed research should include both surgical and rehabilitation strategies that create a cohesive project. Surgical strategies are reconstruction and repair and/or application of biologics, pharmaceuticals, and devices for the purpose of restoration of native architecture, composition, and function of traumatically injured tissues. Rehabilitative strategies are those that restore function following injury or illness, with the goal of optimal health and independence. Projects should integrate principles and approaches from surgical and rehabilitative strategies, beyond what each approach would provide by itself, with the goal of optimizing form, function, and independence for those who have sustained traumatic orthopaedic injuries. The rehabilitation strategy and the standard of care must be specified. Projects that follow patients across the continuum of care are highly encouraged. To encourage meaningful and productive multidisciplinary collaborations, projects submitted for this option must include at least one investigator with orthopaedic rehabilitation expertise and at least one clinician who specializes in orthopaedic or trauma care. A Letter of Collaboration is required from each specialist (i.e., rehabilitation expert and surgeon) who is serving as Key Personnel, excluding the Principal Investigator (PI), on the application. A clinician is defined as an individual who is credentialed (possesses the necessary degrees, licenses, and other certifications) and practicing as a care provider in a relevant capacity.If the proposed research includes a clinical trial of an investigational product to be conducted at international sites, an application to the relevant national Regulatory Agency of each host country must be submitted within 6 months of the award date.The government reserves the right to withdraw funding if an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application and/or international regulatory application is necessary but has not been submitted within 6 months of the award date.For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf.Key aspects of the PRORP CTA mechanism: Clinical Trial Start Date: The proposed clinical trial is expected to begin no later than 6 months after the award date, or 12 months after the award date for studies regulated by the Regulatory Agency. Preliminary Data Are Required: Inclusion of preliminary data relevant to the proposed clinical trial is required. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Intervention Availability: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study. Personnel and Environment: The application should demonstrate the study teams expertise and experience in all aspects of conducting clinical trials, including appropriate statistical analysis, knowledge of U.S. Food and Drug Administration (FDA) processes (if applicable), and data management. The application should include a study coordinator(s) who will guide the clinical protocol through the local IRB of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. The application should show strong institutional support and, if applicable, a commitment to serve as the FDA regulatory sponsor, ensuring all sponsor responsibilities described in 21 CFR 312, Subpart D, are fulfilled. Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projections that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If required by a Regulatory Agency, the trial must use a 21 CFR 11-compliant database and appropriate data standards.Womens Health Research: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health.Use of DOD or VA Resources: If the proposed research involves access to DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.For the purposes of this funding opportunity, Regulatory Agency refers to the FDA or any relevant international Regulatory Agency unless otherwise noted.If the proposed clinical trial involves the use of a drug that has not been approved by the relevant Regulatory Agency for the country where the research will be conducted, then submission of an IND application, or equivalent, that meets all requirements under 21 CFR 312 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the relevant Regulatory Agency if an IND, or equivalent, is not required. If an IND, or equivalent, is required, the regulatory application must be submitted to the relevant Regulatory Agency within 6 months of the CTA award start date. The IND, or equivalent, should be specific for the product and indication to be tested in the proposed clinical trial. For more information on IND applications specifically, the FDA has provided guidance at https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application.If the investigational product is a device, then submission of an IDE, or equivalent, application that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence if an IDE, or equivalent, is not required. If an IDE, or equivalent, is required, the IDE application, or equivalent, must be submitted to the relevant Regulatory Agency within 6 months of the CTA award start date. The IDE, or equivalent, should be specific for the device and indication to be tested in the proposed clinical trial.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP CTA should not exceed $2.5M (Research Level 1) or $3.25M (Research Level 2). Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $13.25M to fund approximately four Research Level 1 and one Research Level 2 CTA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports interdisciplinary research teams to explore how medical devices can effectively relieve chronic pain while minimizing addiction risks.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term but must move beyond a minor advancement and have the potential to lead to a fundamentally new approach that is significantly more effective than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the program announcement, and not on the amount of the budget.The current program announcement discusses the Breakthrough Award Levels 1 and 2. Funding Levels 3 and 4 are available under other program announcements (HT942524BCRPBTA3 and HT942524BCRPBTA4, respectively). The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award program announcement before submitting the pre-application. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under the current program announcement: Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem. To foster research that yields new avenues of investigation, preliminary data are not required. Proof of concept is the anticipated outcome. Funding Level 2: Research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within thebreast cancer landscape. Funding Level 2: Population Science and Prevention Studies: Population Science and Prevention Studies should involve investigations into why certain human patient populations differ in cancer risk or clinical prognosis. The studies should focus on the analysis of human data and biospecimens. Research should be already supported by substantial preliminary or published data and strongly validate clinical translation in a well-defined context within the breast cancer landscape. With compelling justification, population science and prevention studies may request higher levels of funding and an additional year in the period of performance.Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive partnerships between investigators. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. It is expected that funding will be balanced between both PIs unless appropriately justified. New partnerships are encouraged, but not required. The application is expected to describe how the PIs unique expertise combined as a partnership will better address the research question, how the unique expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from being named as a Partnering PI on multiple Breakthrough Award Levels 1 and 2 applications unless they are clearly unique, meaningful partnerships addressing distinct research questions. Applications in which a mentor and their current postdoctoral fellow or junior investigator are named as Initiating and Partnering PIs do not meet the intent of the Partnering PI Option. Applications where one PI is providing samples, animal models, or investigational agents while the other PI is conducting most, or all of the experiments and analyses, do not meet the intent of the Partnering PI Option. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.Personnel: Applications are expected to include an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.Research involving human subjects and research involving human anatomical substances and data is permitted; however, clinical trials are not allowed under this funding opportunity.Applications seeking support for a clinical trial may be submitted to the FY24 BCRP Breakthrough Award Level 3 and Level 4 program announcements (HT942524BCRPBTA3 and HT942524BCRPBTA4, respectively).A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Funding Level 1 should not exceed $450,000 for applications with a single PI or $750,000 if applying under the Partnering PI Option.The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Level 2 should not exceed $1.0M for applications with a single PI or $1.5M if applying under the Partnering PI Option.The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Funding Level 2, Population Science and Prevention Studies, should not exceed $1.5M for applications with a single PI or $2.0M if applying under the Partnering PI Option. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $20.9M to fund approximately 14 Breakthrough Award Levels 1 and 2 applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

A. PROGRAM DESCRIPTION The U.S. Embassy Kyiv / EUR Bureau of the U.S. Department of State announces an open competition for organizations to submit applications for supporting the Mission Ukraine American Spaces Network to help rebuild and restore specific spaces. Please follow all instructions below. Priority Region: Ukraine Program Objectives: The aim of this project is to assist in the restoration of damaged American spaces in Ukraine and to strengthen capacity building and programming at 23 American Spaces. These spaces comprise nine Window on America Centers (American Corners) located in Kropyvnytsky, Kharkiv, Mykolaiv, Mariupol, Slovyansk, Uzhhorod, Vinnytsia, and Zaporizhzhia, and 14 Window on America Centers (affiliated AS) situated in Cherkasy, Chernivtsi, Chernihiv, Dnipro, Ivano-Frankivsk, Kherson, Khmelnytsky, Kyiv, Lutsk, Rivne, Sumy, Ternopil, Zhytomyr and Starobilsk. American Spaces serve as active platforms for educational, cultural, and outreach programs facilitated by the U.S. Embassy in Ukraine. The recipient organization will be responsible for completing a needs assessment of the physical damage done to the entire network of 23 spaces, in cooperation with the Embassy and the network of 23 spaces. restoring any number of those damaged American spaces in Ukraine and enhancing capacity building and programming of the chosen number of spaces. This project seeks to enhance the capacity of American Spaces to deliver quality and innovative programming amidst Russias full-scale invasion and partial occupation of Ukraine, along with intense political and economic pressures. It aims to establish welcoming and technology-equipped American spaces that support Ukraines resilience to disinformation, promote media literacy, advocate for political and economic reforms towards European integration, foster mutual understanding between Ukraine and the United States, and cultivate a more inclusive and cohesive Ukrainian society in response to the Russian-Ukrainian war circumstances. This funding will enable American Spaces to address their basic technology requirements and implement necessary upgrades to facilitate online and offline programs promoting shared Ukrainian and U.S. values, aligning with priority mission goals, and meeting the needs of local communities. Program Objectives: Complete a needs assessment of the entire network to determine the approximate scope of work needed for each space to return to pre-invasion levels of functioning. Restore and renovate any number of damaged American Spaces. After examining the American Spaces network status and needs, the recipient executes renovation of a targeted number of damaged American Spaces;apos; premises paying special attention to their accessibility. Bolster capacity building by establishing welcoming and technology-equipped American Spaces. Replace furniture, make light system/fixture upgrades to make the space flexible enough for online and offline programs, and group after the recipient examines their status and needs. Update signage and appearance of the spaces to clearly demonstrate an American look and feel. Purchase the technical supplies needed to provide effective online and offline programming after the recipient examines their status and needs. Ensure administrative support from the recipient through consultations online and in person, visits, etc. necessary to conduct renovations, replace furniture, make light system/fixture upgrades, update signage and appearance of their spaces, and to use equipment. Ensure each American Space conducts programs on each of the following themes: countering disinformation, skill building including English language skills, Ukraine;apos;s reforms aimed at European integration, civil society initiatives and building a more inclusive and cohesive society, educating audiences on academic and professional exchange opportunities, helping IDP and veteran communities with skill building and psychological support. Strengthen communication and collaboration within the American Spaces network -- America Houses Kyiv, Lviv, and Odesa and Window on America Centers -- by organizing and participating in joint online programs, organizing working visits to explore the best solutions for an American look and feel, and determining technology needs for effective and innovative programming. The U.S. Embassy will be substantially involved in program activities, as this award will be a cooperative agreement. This involvement will include but is not limited to: Guidance on American Spaces mission, policy priorities and strategic planning for program development. Guidance and oversight of America Spaces network development. Approval of American Spaces renovations plans. Approval of major supply purchases, including but not limited to computers, as well as major equipment and furniture purchases. Approval American Spaces communication plans, such as branding/logo changes. Guidance on State Department film licensing and screening agreements. Guidance on State Department data collection and reporting requirements regarding events, participants, and total number of visitors (virtual and in-person) at American Spaces. Provision of access to Overdrive, ELibraryUSA databases, newsletters, and other State department-produced products and activities Approval of any plans for the Recipient to earn income as a result of this award. Participants and Audiences: Intended audiences should vary by program and specific activity. However, in general, the American Spaces are geared toward youth engagement, i.e., Ukrainians aged 15-40. B. FEDERAL AWARD INFORMATION Length of performance period: up to 18 months Number of awards anticipated: one award Total available funding: $250,000.00 Type of Funding: AEECA FY 24 Anticipated program start date: August 1, 2024 This notice is subject to availability of funding. Funding Instrument Type: Cooperative agreement. Cooperative agreements are different from grants in that Embassy staff are more actively involved in the grant implementation. Examples of substantial involvement are included in detail above. Program Performance Period: Proposed program should be completed in max 18 months. C. ELIGILIBITY INFORMATION 1. Eligible Applicants The following organizations are eligible to apply: U.S. or Ukrainian public or private not-for-profit organizations. Applicants must be able to demonstrate experience working in Ukraine and should have a legally registered local office to provide program oversight. The applicant organization must be able to demonstrate the ability to administer all components of the program as outlined in this solicitation, and in cooperation with the U.S. Embassy in Kyiv. 2. Cost Sharing or Matching Cost sharing is highly encouraged; however, it is not a requirement of an application in response to this funding announcement. 3. Other Eligibility Requirements In order to be eligible to receive an award, all organizations must have a Unique Entity Identifier (UEI) number issued via www.SAM.gov as well as a valid registration on www.SAM.gov. Please see Section D.3 for more information. D. APPLICATION AND SUBMISSION INFORMATION see attached full NOFO for all details.

This funding opportunity provides additional financial support to active health services research projects facing unforeseen costs, helping researchers continue their work effectively.

This funding opportunity is designed to support multidisciplinary teams in developing innovative therapies and medical devices for treating visual system diseases, advancing promising preclinical research towards clinical application.

The OCRP Investigator-Initiated Research Award is intended to support high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. The application must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Applications must include preliminary data that are relevant to ovarian cancer and support the proposed research project. These data may be unpublished or from the published literature.

This funding opportunity supports independent research projects that aim to improve health outcomes and promote health equity through innovative and inclusive approaches, particularly in nursing and related fields.

The DWS Grant Program has been established to help individuals with low to moderate incomes finance the costs of household water wells and individually owned decentralized wastewater systems that they own or will own. Grant funds must be used to establish and maintain a revolving fund to provide loans and sub-grants to eligible individuals for individually owned water well systems and/or individually owned wastewater systems. Individual households may use the loan and/or sub-grant funds to construct, refurbish, rehabilitate, or replace decentralized water systems up to the point of entry to a home. Point of entry for the well system is the junction where water enters into a home water delivery system after being pumped from a well. For septic systems, in lieu of the point of entry, the point of exit is substituted. The point of exit is the junction where wastewater exits out of the home wastewater collection system into the septic tank and drain field. Grant funds may be used to pay administrative expenses associated with providing DWS loans and/or sub-grants.

This funding opportunity provides financial support to U.S. and Cabo Verdean non-profit organizations for projects that strengthen cultural ties and promote mutual understanding between the two countries.

This funding opportunity provides financial support for conferences and meetings focused on improving workplace safety and health by addressing critical research priorities in occupational safety and health.

The "Strengthening Workers' Rights in Malaysia's Electronic Supply Chain" grant aims to provide $3 million for a project in Malaysia that supports workers and their organizations in advocating for improved occupational safety, health standards, and gender-responsive standards, while also addressing gender-based violence and harassment in the electronics sector through increased union participation and collective bargaining.

The Bureau of Counterterrorism (CT) of the U.S. Department of State announces an open competition for organizations to submit applications to support the Nigerian interagency in designing, revising, and implementing crisis response plans and protocols. Nigeria is Africa’s largest democracy with a population of over 230 million people and the continent’s largest economy. However, Nigeria currently faces a terrorist threat from primarily the Islamic State of Iraq and Syria West Africa Province (ISIS-WA), the largest ISIS affiliate outside Iraq and Syria, that continues to expand throughout the country. Boko Haram, alQa'ida-aligned Ansaru, and a myriad of gangs and bandit organizations also remain persistent threats. Ensuring that Nigeria’s civilian security services are capable of responding to and managing a crisis is critical to ensuring the safety, stability, and prosperity of the country. This program should identify how the Nigerian interagency prepares crisis response plans, who is involved in that process, and how those plans are tested. CT expects the selected implementer to build the Nigerian interagency’s capacity to develop and/or update these crisis response plans through trainings, mentorship, and simulation exercises and assist the Nigerian interagency with developing their own trainings and exercises to maintain those crisis response plans after the program is over. The application should show an emphasis on interagency coordination in the program’s theory of change and an explanation of how interagency coordination will be assessed and measured. CT is also interested in how the implementer will facilitate sustainability through preparing the Nigerian interagency to institutionalize crisis response reviews. CT can also assist the selected implementer in coordinating and deconflicting program activities with previous foreign assistance programs that worked on this topic. Program Goal: Nigeria’s civilian security services are capable of effectively executing crisis response measures using interagency coordination and institutionalizing emergency management procedures, including the allocation of resources for response activities. Program Objective(s): This program seeks to achieve the following objectives: 1. By 2026, Nigeria has assessed its current interagency coordination efforts and crisis response plans. This objective must be met before the period of performance ends as all other objectives will build on it. 2. By 2027, Nigeria has developed or updated crisis response management plans that delineate roles, responsibilities, and authorities among applicable agencies and/or entities depending on where, when, and what type of crisis has occurred. 3. By 2027, Nigeria’s designated civilian security agencies (noted in Participants and Audiences) and interagency coordination capacities are strengthened through training, exercises, and simulations based on the crisis response plans developed with the assistance of the selected implementer. 4. By 2027, Nigeria’s designated civilian security agencies and interagency coordination capacities are assessed through tabletop exercises to determine the sustainability of crisis response planning, development, and validation procedures. Participants and Audiences: The intended target audience includes Nigeria’s Office of the National Security Advisor, the Department of State Security Services, Nigeria Police Force, Nigeria’s Security and Civil Defense Corps, INTERPOL’s Abuja National Central Bureau, Nigeria’s National Counterterrorism Center, Nigeria Immigration Service, and other Nigerian civilian security agencies and relevant ministries.

This funding opportunity provides financial support for researchers at domestic institutions to study atmospheric processes using data from the Department of Energy's ARM facility, with a focus on improving climate models and understanding critical environmental factors.

This funding opportunity supports researchers investigating the role of T-cells in the central nervous system related to HIV, aiming to understand their impact on viral reservoirs and neurological complications, with a focus on innovative therapeutic strategies.

This funding opportunity supports researchers and educational institutions in developing engineered microbial communities to advance scientific understanding and practical solutions for climate change, sustainability, and biotechnology.